We have the in vivo capabilities required to run mechanistic studies and establish novel in vivo mechanistic models. Capabilities include multiple dosing and sampling routes, microsampling TK capabilities, pathology, metabolism and tissue distribution capabilities, and the full range of mechanistic endpoints (e.g. immunohistochemistry, gene & protein expression, enzyme activity). Novel endpoints are established on request.
Our in-house in vivo capabilities are supported by a full suite of modern laboratory equipment.
This includes two Sciex 6500 triple-quad mass spectrometers, two further triple-quad mass spectrometers, a Xevo G2-XS QTOF/TOF plus a further TOF mass spectrometer. We have the GC, GC-MS and HPLC systems,. advanced microscopy and image analysis, a liquid scintillation counter, quantitative PCR and full capability in Agilent gene analysis and Ingenuity bioinformatics.